The University Hospital St. Marina – Varna is a university hospital in Varna, Bulgaria. The hospital has capacity of 1200 beds.

There are 1,200 beds in MHAT Sv. Marina, EAD.

During the past decade, MHAT Sv. Marina, EAD conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 23 clinical trials were completed, i.e. on average, 143.8% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 11 clinical trials were completed. i.e. 366.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "MHAT Sv. Marina, EAD" #1 sponsor was "Hoffmann-La Roche" with 7 trials, followed by "Bayer" with 5 trials sponsored, "Baxalta now part of Shire" with 3 trials sponsored, "Artu Biologicals" with 2 trials sponsored and "Celgene" with 2 trials sponsored. Other sponsors include 14 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "MHAT Sv. Marina, EAD" #1 collaborator was "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator, "Canadian VIGOUR Centre" with 1 trials as a collaborator, "Cystic Fibrosis Foundation" with 1 trials as a collaborator, "Duke Clinical Research Institute" with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "MHAT Sv. Marina, EAD" are "Hemophilia A" (4 trials), "Hepatitis B, Chronic" (3 trials), "Ulcerative Colitis" (3 trials), "Allergic Rhinoconjunctivitis" (2 trials) and "Hepatitis C, Chronic" (2 trials). Many other conditions were trialed in "MHAT Sv. Marina, EAD" in a lesser frequency.

Most popular intervention types in "MHAT Sv. Marina, EAD" are "Drug" (30 trials), "Biological" (6 trials) and "Other" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Adalimumab" (2 trials), "Oralgen" (2 trials), "RPC1063" (2 trials) and "placebo" (2 trials). Other intervention names were less common.

The vast majority of trials in "MHAT Sv. Marina, EAD" are 34 trials for "All" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "MHAT Sv. Marina, EAD". undefined are not yet recruiting, undefined are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in MHAT Sv. Marina, EAD, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in MHAT Sv. Marina, EAD, 0 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".